Human Longevity Cut Sequencing Price to $599
The firm now offers direct-to-consumer genomic testing, shifting its model toward high-volume preventative screening.
Updated on Oct. 1, 2026 in Healthcare
Live Poll
Do you trust AI-driven models to accurately predict and improve your personal long-term health outcomes?
Human Longevity Inc. has introduced a $599 whole-genome sequencing offering as part of a strategy to pivot toward data-driven, predictive medicine. The company, which maintains a dataset of over 10,000 phenotyped clients, aims to shorten periods of declining health through integrated genomic and biometric assessments.
Why it matters
By lowering the cost of entry significantly below its previous executive health programs, the firm is attempting to scale its predictive health models using larger datasets. This shift targets a transition from high-end niche services toward broad-market preventive care.
The company has lowered its sequencing price to $599, a significant reduction from its previous $8,000 executive health program. The firm, which has raised $500 million in total funding, now supports its diagnostics with a $1 million financial guarantee for missed stage-four cancer diagnoses.
The players
Human Longevity Inc.
A health-tech firm that combines genomic sequencing, imaging, and AI to provide predictive, data-driven preventative medicine.
Wei-Wu He
The executive who assumed operational control of Human Longevity Inc. in 2019 and has invested $70 million into the company.
Insilico Medicine
A biotechnology firm specializing in AI-powered drug discovery and biological modeling that is currently partnering with the company's spin-out.
The details
Human Longevity integrates genomic data with whole-body MRI imaging, blood biomarkers, and wearable sensor inputs to create digital representations of individual biology. To accelerate this work, the firm spun out Human Life Foundation Models, Inc. in May 2026, which has since entered a co-development partnership with Insilico Medicine. The core business relies on a 13-year dataset to refine computational models that predict and mitigate individual health risks.
Timeline
Founded in 2013.
Wei-Wu He took operational control of the company in 2019.
Human Life Foundation Models, Inc. was spun out in May 2026.
Market Landscape
The company’s focus on massive longitudinal phenotyping follows the precedent set by the UK Biobank dataset. By integrating deep biological markers at scale, the firm is attempting to move beyond traditional diagnostics into predictive medicine models.
Operators should monitor whether the move to lower-cost diagnostic tiers drives mass-market adoption or introduces new compliance complexities. If the $1 million care guarantee becomes an industry standard, businesses in the health-screening sector may need to re-evaluate their liability reserves.
The takeaway
The move to lower pricing signals a strategic pivot toward scale, suggesting that proprietary data, rather than individual service fees, is the primary value driver. Operators should track how the firm’s $1 million care guarantee impacts its risk profile and long-term insurance overheads.
Further reading
For more on how data-driven care models are evolving, see Healthcare.
Source note: This article includes information reported by International Business Times.
Live Poll
Do you trust AI-driven models to accurately predict and improve your personal long-term health outcomes?
